Purpose: The goals of this study are to compare NGS-derived transcriptome profiling (RNA-seq) to find out the difference between EZH2 inhibitor treatment and DMSO group in each cancer cell line, and find the relationship between transcriptomes change and drug sensivitity.;	Methods: mRNA profiles of cell lines were generated using  Illumina PE150, then GSEA was used for cellular pathways analysis;	Results:  The result showed 53 common oncogenic signatures were enriched in RNA-seq data. For example, KRAS.300_UP.V1_UP, MEK_UP.V1_UP were statistically enriched in the RNA-seq data. In addition, some oncogenic signatures were only enriched in certain cancer cell lines. For example, 101 and 12 signatures from the RNA-seq were statistically enriched in U2932 and SMMC-7721, respectively.;	Conclusions: Our study systematically examined the cellular transcriptomes affected by EPZ-6438, with biologic replicates, generated by RNA-seq technology. EZH2 inhibition results in the transcriptional activation of multiple onco-pathways in a cell-context dependent manner, which may underline the resistance to EZH2 inhibition. SOURCE: Juan Yan (yanjuan1357@163.com) - Meiyu Geng Shanghai Institute of Materia Medica

Pluto Bioinformatics

GSE119088: Transcriptomes change differerntly in differernt cancer cells upon EPZ-6438 treatment